02646nas a2200457   4500000000100000008004100001260001300042653001000055653002400065653002500089653003800114653001100152653001100163653000900174653001600183653003100199653001300230653003200243653001700275653002800292100001300320700001700333700001800350700001500368700001200383700001200395700001300407700001100420700001300431700002700444700001600471700001400487700002100501700001700522245016300539856007200702300001000774490000800784520138200792022001402174       2013                            d  c2013 Apr10aAdult10aAntigens, Bacterial10aCase-Control Studies10aEnzyme-Linked Immunosorbent Assay10aFemale10aHumans10aMale10aMiddle Aged10aMycobacterium tuberculosis10aPeptides10aSensitivity and Specificity10aTuberculosis10aTuberculosis, Pulmonary1 aAraujo Z1 aGiampietro F1 aBochichio MLA1 aPalacios A1 aDinis J1 aIsern J1 aWaard JH1 aRada E1 aBorges R1 aFernández de Larrea C1 aVillasmil A1 aVanegas M1 aEnciso-Moreno JA1 aPatarroyo MA00aImmunologic evaluation and validation of methods using synthetic peptides derived from Mycobacterium tuberculosis for the diagnosis of tuberculosis infection.  uhttp://www.scielo.br/pdf/mioc/v108n2/0074-0276-mioc-108-02-0131.pdf  a131-90 v1083 a<p>The goal of this study was to demonstrate the usefulness of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of pulmonary tuberculosis (PTB) and extrapulmonary TB (EPTB). This assay used 20 amino acid-long, non-overlapped synthetic peptides that spanned the complete Mycobacterium tuberculosis ESAT-6 and Ag85A sequences. The validation cohort consisted of 1,102 individuals who were grouped into the following five diagnostic groups: 455 patients with PTB, 60 patients with EPTB, 40 individuals with non-EPTB, 33 individuals with leprosy and 514 healthy controls. For the PTB group, two ESAT-6 peptides (12033 and 12034) had the highest sensitivity levels of 96.9% and 96.2%, respectively, and an Ag85A-peptide (29878) was the most specific (97.4%) in the PTB groups. For the EPTB group, two Ag85A peptides (11005 and 11006) were observed to have a sensitivity of 98.3% and an Ag85A-peptide (29878) was also the most specific (96.4%). When combinations of peptides were used, such as 12033 and 12034 or 11005 and 11006, 99.5% and 100% sensitivities in the PTB and EPTB groups were observed, respectively. In conclusion, for a cohort that consists entirely of individuals from Venezuela, a multi-antigen immunoassay using highly sensitive ESAT-6 and Ag85A peptides alone and in combination could be used to more rapidly diagnose PTB and EPTB infection.</p>  a1678-8060